Microsatellite Instability clinical trials
The registry lists 52 studies for Microsatellite Instability across more than 10 countries. 10 are recruiting or about to start. 9 of them are mainly about Microsatellite Instability (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-30.
Get an email when these change. Save the Microsatellite Instability studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
GERCOR - Multidisciplinary Oncology Cooperative Group (3) · Lei Li (3) · Federation Francophone de Cancerologie Digestive (2) · Assistance Publique - Hôpitaux de Paris (2) · Fate Therapeutics (2) · National Taiwan University Hospital (2) · Radboud University Medical Center (2) · M.D. Anderson Cancer Center (2)
What is being tested here
Drugs under test in Microsatellite Instability studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Drug classes tested here Immune checkpoint inhibitors 1 open
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 4
- May 2027Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) · Merck Sharp & Dohme LLC
- May 2027A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors · Vividion Therapeutics, Inc.
- Sep 2027A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors · Marengo Therapeutics, Inc.
- Oct 2027Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Who these studies take
Of the 9 Microsatellite Instability studies recruiting now, 7 (78%) set no upper age limit and 0 (0%) stop at 75 or younger. 0 (0%) take children under 18. 1 (11%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 0 (0%) | 0 (0%) |
| 18 | 9 (100%) | 8 (89%) |
| 30 | 9 (100%) | 8 (89%) |
| 40 | 9 (100%) | 8 (89%) |
| 50 | 9 (100%) | 8 (89%) |
| 65 | 9 (100%) | 8 (89%) |
| 75 | 9 (100%) | 8 (89%) |
| 85 | 8 (89%) | 7 (78%) |
Across all 52 studies, recruiting or not: 10% stop at 75 or younger and 4% at 65; 15% take children; 10% are for women only and 2% for men only; 4% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 50 of 52. Browse all 52 → or search them.
- A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid TumorsRecruitingNCT06004245Phase 111 countries
- Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual DiseaseRecruitingNCT07750158Phase 31 country
- A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid TumorsRecruitingNCT05592626Phase 1/24 countries
- A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.RecruitingNCT06898450Phase 1/28 countries
- Prospective National Cohort Evaluating Predictive Biomarkers of Resistance to Immunotherapy in Patients With MSI/dMMR Metastatic Colorectal Cancer (CORESIM)RecruitingNCT063538541 country
- Neoadjuvant Pembrolizumab With a Watch-and-wait Strategy for dMMR/MSI-H Localized Colon Cancer: PREMICES Study.Not yet recruitingNCT06646445Phase 21 country
- PRODIGE 90 - (FFCD 2204) Neoadjuvant Dostarlimab with Short Course Radiotherapy in a Watch-and-wait Strategy for Microsatellite Unstable or Mismatch Repair-deficient Locally Advanced Rectal Cancer PatientsRecruitingNCT06762405Phase 31 country
- Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus)RecruitingNCT05177133Phase 21 country
- Non-Invasive Diagnosis of Endometrial CancerRecruitingNCT05737797Not applicable1 country
- MMR/MSI Phenotypes in Prediction of Tumor Vaccine Benefit for GliomasRecruitingNCT060432321 country
- National Cohort of Colorectal Cancers With Microsatellite InstabilityCompletedNCT055116881 country
- Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 InhibitorActive, not recruitingNCT03607890Phase 21 country
- Liquid Biopsy Biomarkers for Endoscopic Surveillance in Lynch SyndromeCompletedNCT078382461 country
- TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC.Active, not recruitingNCT04817826Phase 21 country
- Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid CancersActive, not recruitingNCT03935893Phase 21 country
- Development and Validation of the Surgical Assessment and Healthcare (SAH) Index for Gastric Cancer Treatment EvaluationCompletedNCT071809661 country
- Neoadjuvant Prolgolimab Monotherapy in Locally Advanced MMR-deficient Colorectal CancerCompletedNCT06428487Phase 21 country
- Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation StatusCompletedNCT03519412Phase 21 country
- First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined CancersTerminatedNCT06625515Phase 11 country
- QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint InhibitorsActive, not recruitingNCT03228667Phase 21 country
- Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)Active, not recruitingNCT02628067Phase 2
- iRECIST Evaluation's Relevance for DCR in MMR/MSI Metastatic Colorectal Cancer Patients on Nivolumab and IpilimumabActive, not recruitingNCT03350126Phase 21 country
- Dynamics of MSI and Genomic Profile of Colorectal Cancer In the Course of Immune Checkpoint Inhibitor TherapyCompletedNCT064143041 country
- Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma.Active, not recruitingNCT04006262Phase 21 country
- Frequency of Endometrial Cancer Precursors Associated with Lynch SyndromeCompletedNCT052570571 country
- M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite InstabilityCompletedNCT03436563Phase 1/21 country
- Detection of MSI in Circulating Tumor DNA of Colorectal Carcinoma PatientsTerminatedNCT035944481 country
- Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer TypesCompletedNCT03012581Phase 21 country
- Molecular Characteristics of Early-onset Compared With Late-onset Colorectal CancerCompletedNCT06238193
- Cycling in Preventing Colorectal Cancer in Participants With Lynch SyndromeCompletedNCT03495674Not applicable1 country
- Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular ImmunotherapyTerminatedNCT041061671 country
- FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid TumorsCompletedNCT03841110Phase 11 country
- Avelumab Plus 5-FU Based Chemotherapy as Adjuvant Treatment for Stage 3 MSI-High or POLE Mutant Colon CancerTerminatedNCT03827044Phase 31 country
- The Relationship Between Microsatellite Instability and Efficacy of Fluorouracil Based Adjuvant Chemotherapy in Gastric Cancer After OperationCompletedNCT034851961 country
- APL-501 Study for Select Advanced or Relapsed/Recurrent Solid TumorsCompletedNCT03053466Phase 11 country
- Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected CancersCompletedNCT02178722Phase 1/21 country
- Microsatellite Instability in Colorectal CancersCompletedNCT051622481 country
- Diagnosis of Lynch Syndrome Based on Next-generation Sequencing in Colorectal CancerCompletedNCT030472261 country
- A Safety and Tolerability Study of INCAGN02385 in Select Advanced MalignanciesCompletedNCT03538028Phase 11 country
- Genetic Mutation in Recurrent Cervical CancerStatus unknownNCT041912261 country
- Genetic Mutation in Epithelial Ovarian CancerStatus unknownNCT041912521 country
- Aberrant Splicings Due to Microsatellite Instability in Colorectal Cancer : Physiopathological and Clinical ImpactStatus unknownNCT034474311 country
- Clinicopathological Importance of Colorectal Medullary Carcinoma: Retrospective Cohort StudyCompletedNCT03774862
- MSI in Circulatory DNA of Endometrial CancerStatus unknownNCT037449621 country
- Detect Microsatellite Instability Status in Blood Sample of Advanced Colorectal Cancer Patients by Next-Generation SequencingStatus unknownNCT035613501 country
- Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate CancerWithdrawnNCT02966587Phase 21 country
- Postoperative Radiotherapy According to Molecular Analysis of Surgical Margins of Oral and Oropharyngeal SCCStatus unknownNCT00232960Not applicable1 country
- Molecular Biology of Anal Cancer in HIV-Positive PatientsCompletedNCT009528741 country
- Implementation of a New Strategy to Identify HNPCC PatientsStatus unknownNCT00141466Not applicable1 country
- Clinical and Molecular Characterization of Familial Microsatellite Stable Colorectal CancerStatus unknownNCT002202461 country